Related Experiment Videos
Insights
Endothelins (ET), particularly ET-1, are potent vasoconstrictors implicated in cardiac insufficiency and pulmonary hypertension. Blocking ET pathways shows promise in managing heart failure by mitigating vasoconstriction and fluid retention.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
Context:
- Endothelins (ET) are regulatory substances with significant roles in various bodily systems.
- Endothelin-1 (ET-1) is the primary cardiovascular ET and the most potent known vasoconstrictor.
- ET-1 contributes to cardiac hypertrophy, vasoconstriction, impaired relaxation, and reduced contractility in heart failure.
Purpose:
- To elucidate the role of endothelins in cardiovascular pathophysiology, particularly in cardiac insufficiency.
- To evaluate the diagnostic and prognostic utility of ET markers like Big-ET.
- To assess the therapeutic potential of endothelin receptor blockers (ERBs) and endothelin-converting enzyme (ECE) inhibitors in heart failure.
Summary:
- ET-1 plays a critical role in the pathophysiology of cardiac insufficiency, promoting adverse cardiac remodeling and vasoconstriction, and is linked to pulmonary vascular hypertension.
- Big-ET serves as a valuable neurohumoral marker for diagnosing advanced cardiac failure and improving prognostic stratification.
- ET-1's significance in diagnosing cardiac insufficiency appears most pronounced in severe cases.
- Therapeutic strategies involving ET blockade have demonstrated benefits. Non-selective ETA/ETB blockers and selective ETA blockers show favorable effects in cardiac insufficiency.
- Selective ETB blockers may have adverse hemodynamic effects but can prevent fluid retention by suppressing aldosterone.
- Inhibitors of endothelin-converting enzyme (ECE) are a promising therapeutic approach for heart failure, targeting overactivated neurohumoral factors.
Impact:
- Understanding the role of ET-1 in cardiac insufficiency informs diagnostic and prognostic strategies.
- The efficacy of ET blockade in managing heart failure highlights potential therapeutic targets.
- Selective ETB blockade's dual action on hemodynamics and fluid retention warrants further investigation.
- ECE inhibitors represent a novel therapeutic avenue for heart failure, potentially offering a more targeted approach to neurohumoral imbalance.
Abstract:
Endothelins (ET) comprise a group of substances which are produced and have regulatory functions in different systems of the organism. The main cardiovascular ET is ET-1 which is so far the most potent vasoconstrictor substance. In the pathophysiology of cardiac insufficiency ET-1 promotes cardiac hypertrophy, is involved in vasoconstriction, delayed relaxation and reduced left ventricular contractility. The ET-1 level correlates with pulmonary vascular hypertension. By vasoconstriction of renal arteries ET leads to volume retention. Big-ET is a very efficient neurohumoral marker in the diagnosis of developed cardiac failure which can lead to more accurate prognostic stratification. ET-1 is probably important for assessment of the diagnosis of cardiac insufficiency only in severe cardiac failure. The favourable effect of ET block in cardiac insufficiency was proved for the non-selective ETA/ETB blocker and selective ETA blocker. The selective ETB blocker has an adverse haemodynamic effect in treatment of heart failure but by suppression of aldosterone it can prevent fluid retention. In the treatment of cardiac failure blockers of endothelin converting enzyme seem perspective as they reduce adversely activated neurohumoral factors.